MIM
ADCT icon

MetLife Investment Management’s ADC Therapeutics ADCT Stock Holding History

MetLife Investment Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$201K Buy
53,690
+4,008
+8% +$15.8K ﹤0.01% 2224
2025
Q4 		$175K Buy
49,682
+19,633
+65% +$79.7K ﹤0.01% 2335
2025
Q3 		$120K Sell
30,049
-14,978
-33% -$47.2K ﹤0.01% 2573
2025
Q2 		$121K Sell
45,027
-460
-1% -$968 ﹤0.01% 2449
2025
Q1 		$64.1K Buy
45,487
+14,370
+46% +$24.4K ﹤0.01% 2663
2024
Q4 		$61.9K Sell
31,117
-11,972
-28% -$31.3K ﹤0.01% 2721
2024
Q3 		$136K Buy
43,089
+24,279
+129% +$76.6K ﹤0.01% 2486
2024
Q2 		$59.4K Buy
+18,810
New +$74.8K ﹤0.01% 2732

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return